Affymax soars on drug candidate update. After the bell: Depomed in deal with J&J unit Print E-mail
By Staff   
Thursday, 05 August 2010 18:32

Below is a list of the companies that made news in the healthcare sector on Thursday, August 5, 2010.

Depomed, Inc. (Nasdaq:DEPO) after the bell today announced that Janssen Pharmaceutica N.V. has licensed worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to be used for the non-exclusive development of a fixed dose combination formulation of canagliflozin, a Sodium Glucose Transport 2 (SGLT2) inhibitor, and extended-release metformin. Janssen Pharmaceutica has also been granted a right of reference to the GLUMETZA NDA and associated data for use in developing the combination product.

Under the terms of the service agreement, Depomed will formulate the fixed dose combination product. Janssen Pharmaceutica will have the commercialization rights for the combination product. Depomed will receive a $5 million upfront license fee, plus reimbursements for its formulation work on the project and an additional $5 million license fee following completion of Depomed's formulation work. Depomed is eligible for an additional milestone plus a royalty on potential future net sales.

In extended trading shares of Depomed were trading up more than 13 cents.

Earlier in the day:

Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

Affymax and Takeda are continuing to conduct further analysis of the PEARL and EMERALD studies which evaluated the efficacy and safety of Hematide in chronic renal failure patients with anemia. Before year end, the companies plan to discuss with the FDA the U.S. registration strategy for Hematide. Subject to feedback from the FDA, the plan is to pursue a New Drug Application (NDA) for treatment of anemia in dialysis patients, while continuing to evaluate the non-dialysis indication. The timeline for possible submission of the NDA will be aimed for first half of 2011, but will be finalized after the FDA meeting.

Shares of Affymax jumped more than 26%, surging higher by $1.70 to close the day at $8.13.

NewCardio, Inc., (OTC Bulletin Board:NWCI.ob) announced today that QTinno, NewCardio's automated cardiac safety software solution, has been licensed for use in connection with the first, of what is anticipated to be multiple Phase 1 studies, by the U.S. subsidiary of a large global pharmaceutical company.

The total revenue to NewCardio from this initial study, including the license and related professional services, will be approximately $225,000-$275,000, with most of the revenue expected to be recognized during the current quarter ending September 30, 2010.

Vincent Renz, NewCardio's President and Chief Executive Officer, commented, "We are excited to participate in this study. It is significant that the methodology for this study was selected by the pharmaceutical company, who specifically identified QTinno for part of the ECG analysis. We have already implemented and validated QTinno in preparation for processing the ECGs from the study which has already commenced."

Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

The study, entitled "A Phase I/II Trial of AN-152 (AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer", will enroll up to 55 patients and will be conducted in two portions: the first portion will be an abbreviated dose-escalation followed by a single arm, Simon Optimum two-stage design Phase 2 study using the dose selected in the Phase 1 portion. The primary objective of the Phase 2 portion is to evaluate the clinical benefit of AEZS-108 in men with castration- and taxane-resistant metastatic prostate cancer, for which the presence of LHRH receptors has been confirmed.

Biovest International, Inc. (OTCQB: BVTI), a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin’s lymphoma, today announced that the Company has retained the investment banking firm, ROTH Capital Partners, LLC (ROTH). ROTH has been engaged to assist Biovest in raising capital as the Company prepares to emerge from Chapter 11 reorganization.

Dyax Corp. (NASDAQ: DYAX) announced today that results from EDEMA3, the Company’s first Phase 3 trial evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE), were published in the August issue of The New England Journal of Medicine. KALBITOR, discovered and developed by Dyax, is available in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

EDEMA3 was the first of two Phase 3 trials evaluating KALBITOR for the treatment of acute HAE attacks. Results showed a statistically significant improvement of HAE attack symptoms with KALBITOR treatment versus placebo.

Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Robert (Bob) Spiegel, M.D., FACP, to the Company's Board of Directors. Dr. Spiegel was employed at Schering Plough for 26 years where he was deeply involved in clinical research culminating with his position as Chief Medical Officer.

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company with respect to the development and commercialization of two extended topical drug products. The products and terms of the agreement were not disclosed.

Chris Mengler, president of Global Pharmaceuticals, said: "We are excited to collaborate with Perrigo on two extended topical products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today announced it has reconstituted its Scientific Advisory Board with notable key opinion leaders in the MS field. Members of the Advisory Board include Dawn McGuire, M.D. (Chair); Doug Arnold, M.D.; Edward Fox, M.D., Ph.D; Hans-Peter Hartung, M.D.; Clyde Markowitz, M.D.; Paul O’Connor, M.D.; Chris H. Polman, M.D. and Arthur Vandenbark, Ph.D.

"Opexa is developing Tovaxin, a novel immunotherapy for multiple sclerosis, and this board of advisors represents some of the best and most highly regarded neurologists and immunologists in the world. Each has developed substantial expertise relevant to the further development of Tovaxin including designing and participating in numerous MS clinical trials, understanding U.S. and EU regulatory requirements, new product development, and T-cell immunology and their guidance will be instrumental in our ongoing plans to advance Tovaxin," said Neil K. Warma, President and Chief Executive Officer.

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued a positive opinion for RELISTOR (methylnaltrexone bromide) subcutaneous injection in pre-filled syringes. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion for RELISTOR will now be forwarded to the European Commission for a final decision.

Progenics is also seeking approval to market RELISTOR in pre-filled syringes in the U.S. and awaits FDA action. Pending respective approvals in the E.U. and U.S., Progenics expects that pre-filled syringe commercial launches would occur in the United States and European Union in the second quarter of 2011.

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 15 patients have been enrolled into the Phase II portion of the study. Given the favourable biological activity and safety data, the Company intends to expand the present program from 60 to 120 patients at up to six centers in the United States, Canada and Australia, subject to regulatory approval. Detailed safety and activity data for CYT387 are planned to be presented at the American Society of Hematology (ASH) meeting in Orlando, Florida in December this year.

Also Thursday:

Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to market and distribute a high potency, highly concentrated vitamin D-3 capsule. This vitamin can be taken once a week in adjunct with calcium to help reduce bone loss and joint pain.

China Sky One Medical, Inc. (Nasdaq:CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China, today announced that it will conduct a conference call at 8:00 a.m. Eastern Time (ET) on Tuesday, August 10, 2010, to discuss its second quarter of 2010 financial results.

Cornerstone Therapeutics Inc. (Nasdaq:CRTX) a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that its product candidate CRTX-067 is an ANDA filing for a generic 10 mg chlorpheniramine polistirex/8 mg hydrocodone polistirex suspension product that will be a generic substitute for the product currently sold under the Tussionex brand name by UCB, Inc.

Eclipsys Corporation (NASDAQ: ECLP), The Outcomes Company®, today announced that South Nassau Communities Hospital (South Nassau), a 435-bed teaching hospital located in Oceanside, NY, has selected the company's Sunrise Enterprise suite of integrated clinical solutions.

Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the second quarter ended June 30, 2010.

Genta Incorporated (OTCBB: GETAD.OB) announced today that the Company will release its second quarter 2010 financial results on Thursday, August 12, 2010.

GLG Life Tech Corporation (TSX:GLG)(NASDAQ GLGL), the vertically-integrated leader in the agricultural and commercial development of high quality stevia, announces today the appointments of David M. Hall and Dr.Hong Zhao Guang to its Board of Directors.

iBio, Inc. (OTCBB: IBPM) announces the appointment of distinguished infectious disease and vaccine manufacturing and licensing expert Arthur Y. Elliott, PhD, to its board of directors.

InSite Vision Incorporated (OTCBB:INSV) today reported operating and financial results for the quarter ended June 30, 2010.

KraigBiocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, issued a status update today, along with an outline of its key near-term business goals, which management will discuss on a teleconference call at 1:00 p.m. ET today.

Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Thursday, August 12, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the second quarter ended June 30, 2010.

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today reported the results of its se ond quarter of 2010 and six months ended June 30, 2010.

Omnicare, Inc. (NYSE:OCR), one of the nation's leading providers of pharmaceutical care for the elderly, reported today financial results for its second quarter e ded June 30, 2010.

Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference on Friday, August 13, 2010.

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it will release fi ancial results for the quarter ended June 30, 2010 on Wednesday, August 11, 2010, before the U.S. financial markets open.

Sigma-Aldrich® (Nasdaq:SIAL) today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12 at 1:30 p.m. (ET) in Boston.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension.

TRANSCEND SERVICES, INC. (NASDAQ: TRCR) announced today that it has entered into a three-year preferred provider agreement with Child Health Corporation of America (CHCA).

Watson Pharmaceuticals, Inc. (NYSE:WPI) today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus